Xencor (XNCR) Net Income towards Common Stockholders Growth (1y) (2014 - 2026)
Powered by 
Analysis
Xencor (XNCR) Net Income towards Common Stockholders Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -12.04% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 95.87% |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | 29.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.43% |
| Mar 31, 2026 | -164.95% |
| Dec 31, 2025 | 85.60% |
| Sep 30, 2025 | 87.30% |
| Jun 30, 2025 | 55.26% |
| Mar 31, 2025 | 34.34% |
| Dec 31, 2024 | -75.60% |
| Sep 30, 2024 | -95.48% |
| Jun 30, 2024 | -164.51% |
| Mar 31, 2024 | -28.11% |
| Dec 31, 2023 | -118.21% |
| Sep 30, 2023 | 25.92% |
| Jun 30, 2023 | 23.46% |
| Mar 31, 2023 | -345.20% |
| Dec 31, 2022 | -116.50% |
| Sep 30, 2022 | 18.49% |
| Jun 30, 2022 | -165.03% |
| Mar 31, 2022 | 1,048.69% |
| Dec 31, 2021 | 633.64% |
| Sep 30, 2021 | -220.25% |